Btim Corp Decreased Cr Bard Inc (NYSE:BCR) Stake By $13.89 Million

October 13, 2017 - By Marie Mckinney

Investors sentiment decreased to 0.58 in 2017 Q2. Its down 0.30, from 0.88 in 2017Q1. It worsened, as 99 investors sold BCR shares while 273 reduced holdings. 103 funds opened positions while 111 raised stakes. 55.14 million shares or 10.97% less from 61.93 million shares in 2017Q1 were reported. North Mngmt Corp has 800 shares. Chase Inv Counsel has 7,844 shares. Fairview Capital Invest Ltd Com holds 5,526 shares. Moreover, Highvista Strategies Ltd has 3.27% invested in C R Bard Inc (NYSE:BCR). Buffington Mohr Mcneal stated it has 6,970 shares. Oak Ridge Invests Ltd Liability Company invested in 0.16% or 15,595 shares. Canandaigua Retail Bank And Tru holds 0.06% or 1,000 shares. Employees Retirement Association Of Colorado owns 14,299 shares. Iberiabank owns 3,474 shares for 0.33% of their portfolio. Bancshares Of Montreal Can owns 93,465 shares. 1St Source National Bank & Trust accumulated 0.05% or 1,987 shares. 20,348 are held by Texas Permanent School Fund. Btim Corp holds 1.21% or 237,284 shares in its portfolio. Dean Associates Limited Com accumulated 2,646 shares or 0.11% of the stock. Pinnacle Assoc Ltd invested in 0.01% or 1,000 shares.

Btim Corp decreased its stake in Cr Bard Inc (NYSE:BCR) by 18.3% based on its latest 2017Q3 regulatory filing with the SEC. Btim Corp sold 43,412 shares as the company’s stock rose 26.87% with the market. The institutional investor held 193,872 shares of the health care company at the end of 2017Q3, valued at $62.14 million, down from 237,284 at the end of the previous reported quarter. Btim Corp who had been investing in Cr Bard Inc for a number of months, seems to be less bullish one the $23.50B market cap company. The stock rose 0.40% or $1.3 reaching $323.41. About 300,685 shares traded. C R Bard Inc (NYSE:BCR) has risen 40.70% since October 13, 2016 and is uptrending. It has outperformed by 24.00% the S&P500.

Btim Corp, which manages about $6.42B US Long portfolio, upped its stake in Danaher Corp (NYSE:DHR) by 226,912 shares to 235,102 shares, valued at $20.17 million in 2017Q3, according to the filing.

C R Bard Inc (NYSE:BCR) Ratings Coverage

Among 15 analysts covering CR Bard (NYSE:BCR), 4 have Buy rating, 0 Sell and 11 Hold. Therefore 27% are positive. CR Bard has $31700 highest and $190 lowest target. $252.67’s average target is -21.87% below currents $323.41 stock price. CR Bard had 30 analyst reports since August 27, 2015 according to SRatingsIntel. The firm earned “Overweight” rating on Tuesday, January 3 by Morgan Stanley. On Thursday, August 27 the stock rating was upgraded by Goldman Sachs to “Neutral”. The stock has “Hold” rating by Jefferies on Tuesday, September 12. The firm earned “Buy” rating on Thursday, September 15 by Evercore. The rating was maintained by Needham on Friday, September 22 with “Hold”. Raymond James upgraded the shares of BCR in report on Thursday, January 5 to “Strong Buy” rating. The stock has “Outperform” rating by Wells Fargo on Friday, September 16. As per Thursday, March 17, the company rating was initiated by Nomura. BMO Capital Markets maintained C R Bard Inc (NYSE:BCR) on Monday, July 10 with “Hold” rating. The firm earned “Buy” rating on Thursday, November 12 by Citigroup.

C. R. Bard, Inc. is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The company has market cap of $23.50 billion. The Firm operates through the manufacture and sale of medical devices segment. It has a 42.45 P/E ratio. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Another recent and important C R Bard Inc (NYSE:BCR) news was published by Businessinsider.com which published an article titled: “EU mergers and takeovers (Oct 13)” on October 13, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.